Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 7/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898362 | 1.00 | FAAH (0.50) | FAAHCES1CES2DGKAMEN1 | |
| SCHEMBL8062961 | 0.98 | FAAH (0.48) | FAAHCES1CES2DGKAMEN1 | |
| SCHEMBL67891 | 0.84 | ALDH1A1 (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7593373 | 0.82 | FAAH (0.55) | FAAHCES1CES2DGKAMEN1 | |
| SCHEMBL27429395 | 0.82 | FAAH (0.55) | FAAHCES1CES2DGKAMEN1 | |
| SCHEMBL28767623 | 0.81 | FAAH (0.53) | FAAHCES1CES2DGKAMEN1 | |
| SCHEMBL1216447 | 0.80 | FAAH (0.54) | FAAHCES1CES2DGKAMEN1 | |
| SCHEMBL28311100 | 0.79 | FAAH (0.52) | FAAHCES1CES2DGKAMEN1 | |
| SCHEMBL2334337 | 0.79 | ALDH1A1 (0.56) | FAAHCES1HSD17B10TSHRLMNA | |
| SCHEMBL28794167 | 0.79 | DGKA (0.55) | CES1CES2DGKAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9895379-B2 | 17alpha, 21-dihydroxypregnene esters as antiandrogenic agents | CASSIOPEA S.P.A. (IT) | 2018-02-20 | — | — | US | disclosed |
| US-20160263127-A1 | 17 Alpha, 21-Dihydroxypregnene Esters as Antiandrogenic Agents | COSMO DERMATOS SRL. (IT) | 2016-09-15 | — | — | US | disclosed |
| US-9211295-B2 | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents | CASSIOPEA S.P.A. (IT) | 2015-12-15 | — | — | US | disclosed |
| US-20150216878-A1 | 17 Alpha, 21-Dihydroxypregnene Esters as Antiandrogenic Agents | CASSIOPEA S.P.A. (IT) | 2015-08-06 | — | — | US | disclosed |
| US-8865690-B2 | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents | COSMO DERMATOS SRL (IT) | 2014-10-21 | — | — | US | disclosed |
| US-20140154306-A1 | 17ALFA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS | COSMO S.P.A. (IT) | 2014-06-05 | — | — | US | disclosed |
| US-20120149671-A1 | 17ALPHA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS | COSMO SPA, (IT) | 2012-06-14 | — | — | US | disclosed |
| US-8143240-B2 | 17α, 21-dihydroxypregnene esters as antiandrogenic agents | COSMO S.P.A. (IT) | 2012-03-27 | — | — | US | disclosed |
| US-20090264396-A1 | 17Alpha, 21-Dihydroxypregnene esters as antiandrogenic agents | COSMO SPA (IT) | 2009-10-22 | — | — | US | disclosed |
| EP-1421099-B1 | 17ALFA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS | COSMO SPA (IT) | 2005-02-16 | — | — | EP | disclosed |
| US-20050026889-A1 | Treating acne, seborrhea, hirsutism, alopecia, mastodynia, prostate hyperplasia and carcinoma, virilization syndromes in the female, early puberty, use in inhibition of sexual aggressiveness in the male, male contraception | COSMO SPA. (IT) | 2005-02-03 | — | — | US | disclosed |
| EP-1421099-A1 | 17ALFA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS | Cosmo S.p.A. (IT) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003014141-A1 | 17ALFA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS | COSMO S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| WO-1994019309-A1 | A NOVEL METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE COMPOUNDS AS WELL AS NOVEL END PRODUCTS | MAEENSIVU EIJA (FI) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263127-A1 | 17 Alpha, 21-Dihydroxypregnene Esters as Antiandrogenic Agents | HSD17B11, CYP17A1, NR5A1 | FAAH 3235/4885CES1 127/4885CES2 1084/4885 |
| US-20050026889-A1 | Treating acne, seborrhea, hirsutism, alopecia, mastodynia, prostate hyperplasia and carcinoma, virilization syndromes in the female, early puberty, use in inhibition of sexual aggressiveness in the male, male contraception | CYP17A1, CYP19A1, HSD17B3 | FAAH 406/4885CES1 645/4885CES2 1340/4885 |
| US-20140154306-A1 | 17ALFA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS | NR5A1, CYP17A1, HSD17B11 | FAAH 3236/4885CES1 220/4885CES2 1844/4885 |
| US-20090264396-A1 | 17Alpha, 21-Dihydroxypregnene esters as antiandrogenic agents | HSD17B11, NR5A1, CYP17A1 | FAAH 3153/4885CES1 160/4885CES2 1910/4885 |
| US-20150216878-A1 | 17 Alpha, 21-Dihydroxypregnene Esters as Antiandrogenic Agents | HSD17B11, CYP17A1, NR5A1 | FAAH 3213/4885CES1 156/4885CES2 1854/4885 |
| US-20120149671-A1 | 17ALPHA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS | HSD17B11, NR5A1, CYP17A1 | FAAH 3148/4885CES1 158/4885CES2 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.